Microsoft, weight loss drug sales, and GSK profits surge


In today’s episode, Ian King speaks with Dan Ives – managing director of the brokerage and advisory firm Wedbush Securities – to discuss Microsoft’s revenues and AI.

Ian Johnston, global pharmaceutical correspondent at the Financial Times, discusses sales of popular weight loss drug ‘Wegvoy’, made by Novo Nordisk – as they say their sales almost quadrupled last year.

And, Ian discusses GSK’s operating profit of £8.8bn for 2023 with strong selling medicines including its HIV and shingles medication.

Articles You May Like

Solar to meet half of global electricity demand growth in 2024 and 2025
Jeep to challenge Rivan, Tesla Cybertruck with the Gladiator EV pickup
Police officer stabbed in chest at Category A prison
Elon delays Optimus, Hyundai gets nervous, and a REAL work truck
Biden wants to pass the baton to Harris to take on Trump – but it’s complicated